Paratek Pharmaceuticals acknowledges receipt of NexPoint letter

Paratek Pharmaceuticals acknowledged receipt of a letter from NexPoint Asset Management, L.P., together with its affiliates. In a statement, the company said: “Paratek appreciates receiving constructive feedback from its stockholders and as such, has actively engaged with NexPoint over the past several months. However, Paratek’s board of directors respectfully disagrees with NexPoint’s characterizations contained in its letter. Paratek looks forward to providing stockholders with additional details with respect to the previously announced acquisition of Paratek by Gurnet Point Capital and Novo Holdings A/S when it files its proxy materials with the Securities and Exchange Commission.”